Home>Topics>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR AZN

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Incyte: Increasing Sales, Deep Pipeline, Multiple Catalysts, With A Side Of M&A Chatter

      Headlines

      Fri, 19 Sep 2014

      By R.S. Analytics : Incyte Corp. (NASDAQ: INCY ) is a biopharmaceutical company focusing on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. Incyte currently has one drug on the market, a deep pipeline, and multiple ...

    2. Unilife: A Medical Device Company Poised For Major Upside On New Revenue Streams

      Headlines

      Fri, 19 Sep 2014

      By RightEdge Analytics : Background: Unilife Corporation (NASDAQ: UNIS ) is a designer and manufacturer of injectable drug delivery systems worldwide. Unilife offers a diverse product line to satisfy the deployment of drugs ranging from stable vaccines to complex biologics. The whole delivery ...

    3. EC clears Xultophy

      Headlines

      Fri, 19 Sep 2014

      insulin degludec ( Tresiba ) and liraglutide ( Victoza ). Novo plans to launch the product in Europe in 1H 2015. Related tickers: (NYSE: NVS ) (NYSE: LLY ) (NYSE: MRK ) (NYSE: SNY ) (NYSE: AZN ) (NYSE: GSK ) Post your comment!

    4. BRIEF-Ypsomed says newly supplies AstraZeneca with Bydureon Pen

      Headlines

      Fri, 19 Sep 2014

      Sept 19 (Reuters) - Ypsomed Holding AG : * Says AstraZeneca will use Ypsomed injection system for subcutaneous ad-

    5. FDA clears Trulicity

      Headlines

      Thu, 18 Sep 2014

      is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. Related tickers: ( NVS +0.1% ) ( MRK +0.7% ) ( SNY +0.7% )( AZN +1.3% )( GSK +0.4% ) Post your comment!

    6. BRIEF- Astrazeneca says U.S. FDA approves Movantik tablets

      Headlines

      Tue, 16 Sep 2014

      * US FDA approved Movantik (Naloxegol) tablets C-II as first once-daily oral peripherally-acting mu-opioid receptor antagonist (pamora) medication

    7. Update: AstraZeneca Announces Licensing Agreement

      Headlines

      Tue, 16 Sep 2014

      By Trevor Lowenthal : In early June I wrote a bullish article on AstraZeneca (NYSE: AZN ), with a thesis stating that the company's extensive oncology pipeline as well as its attractive buyout prospects in light

    8. CORRECTED-FDA approves AstraZeneca , Nektar constipation drug

      Headlines

      Tue, 16 Sep 2014

      Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc .

    9. FDA clears OIC drug

      Headlines

      Tue, 16 Sep 2014

      induced constipation who take opioids for the management of chronic non-cancer pain. Movantik is distributed by AstraZeneca ( AZN -0.9% ). Related tickers: ( PGNX -0.2% ) ( SLXP +3.7% ) ( CBST +0.1% ) Post your comment!

    10. AstraZeneca , Eli Lilly partner up on Alzheimer's drug

      Headlines

      Tue, 16 Sep 2014

      partner for its experimental Alzheimer's drug, AstraZeneca (NYSE: AZN ) has now agreed to team up with Eli Lilly (NYSE ..... Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M, depending on the progress of the

    « Prev12345Next »
    Content Partners